BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory existed for all hypotheses. The results of their experimentation yielded the understanding that inoculation coupled with reactance-enhanced messages leads to "stronger resistance effects" (p. 148). Consistent with the medical analogy of inoculation theory, Miller, et al. (2013) liken reactance-enhanced messages to a "booster shot," increasing the success of the inoculation. Another unique feature of the study is examining low-controlling language versus high-controlling language and its impact on affect and source credibility. Similarly, Miller, et al. (2007) utilizes psychological reactance theory (Brehm, 1966, 1972; Brehm & Brehm, 1981) to avoid or eliminate source derogation and message rejection. In this study, their